论文部分内容阅读
亚临床肝癌(SCHCC)是指无明确肝癌症状与体征的肝癌。绝大多数是甲胎蛋白(AFP)或超声显像普查发现,病变大多为≤5cm的小肝癌。手术切除率高,死亡率明显下降,使肝癌预后大为改观。一、研究亚临床肝癌的意义:1.证明肝癌是可能治愈的,不少已恢复工作,结婚并生育,同时也是获得肝癌长生存者的最有效途径。2.是提高肝癌总预后的最重要途径。对比我院1958～1966年,1967～1975年和1976～1984年三个阶段,因SCHCC在全组中所占比例由0％,7.2％增至21.2％,全组5年生存率亦由1.7％,7.1％增至19.5％。3.效益提高10倍。全组5年生存率临床肝癌仅4.2％,而SCHCC则达43.9％。4.SCHCC的研究导致了对肝癌三早、肝癌预后,肝癌自然病程、肝癌发生与发展等一系列概念的更新。5.SCHCC研究有力促进了临床与基础研究,反映了对肝癌认识与治疗上的重大进
Subclinical liver cancer (SCHCC) refers to liver cancer without clear liver cancer symptoms and signs. The vast majority of patients were diagnosed with alpha-fetoprotein (AFP) or ultrasound imaging. Most of the lesions were small hepatocellular carcinomas < 5 cm. The high rate of surgical resection and the significant decrease in mortality have greatly improved the prognosis of liver cancer. First, study the significance of subclinical liver cancer: 1. Prove that liver cancer is likely to be cured, many have resumed work, get married and give birth, but also the most effective way to obtain long-term survivors of liver cancer. 2. It is the most important way to improve the overall prognosis of liver cancer. Compared with 1958-1966, 1967-1975 and 1976-1984, the proportion of SCHCC in the whole group increased from 0% to 7.2% to 21.2%. The 5-year survival rate of the whole group was also 1.7. %, 7.1% to 19.5%. 3. Benefits increase 10 times. The 5-year survival rate of the whole group was only 4.2% of the clinical liver cancer, while SCHCC was 43.9%. 4. The research of SCHCC led to the updating of a series of concepts such as the early stage of liver cancer, the prognosis of liver cancer, the natural course of liver cancer, and the occurrence and development of liver cancer. 5.The study of SCHCC strongly promoted clinical and basic research, reflecting a major advance in understanding and treatment of liver cancer.